Revenue in the period increased 7. 7 per cent to $US5. 33bn. "We continue to see robust global demand for plasma therapies," CSL chief executive Paul Perreault said.
Blood products maker CSL posted a 7. 8 per cent jump in full-year profit as sales of immunoglobulin products surged 12 per cent amid robust market conditions.
Alan has been a trusted source of investment advice to Australians for many years, and in 2005 he founded Eureka Report - Australia’s #1 online investment report.
Read more here: Business Spectator